Souhaitez-vous accéder aux communiqués récents ?

HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines...

BOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the...

Indianapolis, March 10, 2025 (GLOBE NEWSWIRE) -- Longevity Life Advisors announces the launch of CancerEDGE, a first-of-its-kind program designed to provide genomic testing and precision health...

Cybrexa presented new data from its clinical-stage alphalex™ peptide-drug conjugate technology at ESMO Targeted Anticancer Therapies Congress 2025.

NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or the "Company"), a clinical stage biopharmaceutical company dedicated to meeting unmet medical...

BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce...

Cybrexa announces the first patient has been dosed in a Ph2 clinical trial evaluating CBX-12 in women with platinum-resistant or refractory ovarian cancer.

Press Release Qubit Pharmaceuticals nominated for "Best start-up" award at Prix Galien USA 2024 - Qubit Pharmaceuticals has been nominated for the 2024 edition of the prestigious Prix Galien USA, in...

Press release Qubit Pharmaceuticals selected as one of the 100 Technology Pioneers 2024 by the World Economic Forum Qubit Pharmaceuticals joins the prestigious community of 100 disruptive...

HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial in AML, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine